Innate Pharma SA
IPHA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001598599
No open-market purchases or sales by Innate Pharma SA insiders were filed in the last 90 days; 10 institutions reported holding it in 13F filings for Q2 2026, worth $354.0K in total; no superinvestor holds it.
Other share classesIPHYF
13F holders, Q1 2022
Institutional positions in Innate Pharma SA as of Mar 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 13
- −3 vs. Q4 2021
- Shares held
- 952.3K
- −437.9K (−31.5%) vs. Q4 2021
- Total value
- $3.20M
- −$3.32M (−50.9%) vs. Q4 2021
- New holders
- 2
- 4 more added
- Sold out
- 5
- 5 more reduced
Compare with Q4 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting IPHA on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 10 | $354.0K |
| Q1 2026 | 9 | $235.5K |
| Q4 2025 | 11 | $483.5K |
| Q3 2025 | 9 | $157.9K |
| Q2 2025 | 9 | $178.7K |
| Q1 2025 | 10 | $281.6K |
| Q4 2024 | 9 | $254.8K |
| Q3 2024 | 8 | $545.1K |
| Q2 2024 | 8 | $469.0K |
| Q1 2024 | 9 | $731.3K |
| Q4 2023 | 8 | $361.0K |
| Q3 2023 | 8 | $805.6K |
| Q2 2023 | 9 | $735.6K |
| Q1 2023 | 9 | $1.13M |
| Q4 2022 | 11 | $1.49M |
| Q3 2022 | 12 | $1.89M |
| Q2 2022 | 13 | $2.58M |
| Q1 2022 | 13 | $3.20M |
| Q4 2021 | 16 | $6.52M |
| Q3 2021 | 18 | $5.82M |
| Q2 2021 | 5 | $296.0K |
| Q1 2021 | 7 | $759.8K |
Institutions, Q1 2022
Shares, value and share of portfolio for each institution holding Innate Pharma SA; share changes are against Q4 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock Inc. | 504,408 | $1.70M | 0.00% | +108,335+27.4% | Added |
| Bank of America Corp | 175,184 | $589.0K | 0.00% | −71,867−29.1% | Reduced |
| Alps Advisors Inc | 83,966 | $282.0K | 0.00% | −9,752−10.4% | Reduced |
| Morgan Stanley | 44,954 | $151.0K | 0.00% | +5,624+14.3% | Added |
| Optiver Holding B.V. | 38,974 | $131.0K | 0.00% | −148,282−79.2% | Reduced |
| Jane Street Group, LLC | 37,736 | $127.0K | 0.00% | +23,012+156.3% | Added |
| Two Sigma Investments, LP | 36,089 | $121.0K | 0.00% | −30,966−46.2% | Reduced |
| Millennium Management LLC | 25,115 | $84.0K | 0.00% | −29,906−54.4% | Reduced |
| Barclays PLC | 3,411 | $11.0K | 0.00% | +3,411 | New |
| Advisor Group Holdings, Inc. | 1,000 | $3.00K | 0.00% | 00.0% | Unchanged |
| Captrust Financial Advisors | 905 | $3.00K | 0.00% | +905 | New |
| Steward Partners Investment Advisory, LLC | 500 | $2.00K | 0.00% | 00.0% | Unchanged |
| Citigroup Inc | 55 | $0 | 0.00% | +11+25.0% | Added |
| Silverarc Capital Management, LLC | 0 | $0 | 0.00% | −184,046−100.0% | Sold out |
| Pura Vida Investments, LLC | 0 | $0 | 0.00% | −79,896−100.0% | Sold out |
| Two Sigma Advisers, LP | 0 | $0 | 0.00% | −12,300−100.0% | Sold out |
| Virtu Financial LLC | 0 | $0 | 0.00% | −11,740−100.0% | Sold out |
| Tower Research Capital LLC (TRC) | 0 | $0 | 0.00% | −410−100.0% | Sold out |